Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00002153

Enrollment

Registered

2001-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Lymphoproliferative Disorders, Sarcoma, Kaposi

Keywords

Skin Neoplasms, Sarcoma, Kaposi, Acquired Immunodeficiency Syndrome, Antineoplastic Agents

Brief summary

To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.

Interventions

DRUGA-007

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

Concurrent Medication: Allowed: * Maintenance antihormones, hormones, and glucocorticoids. Patients must have: * Histologically proven metastatic cancer including Kaposi's sarcoma and lymphoproliferative disorders to the skin or cutaneous sites. NOTE: * Primary basal or squamous cell cancer of the skin is allowed. * Failed both primary and secondary chemotherapy and/or immunotherapy protocols. * Measurable skin or cutaneous lesions. 4 Life expectancy of at least 20 weeks. Prior Medication: Required: * Prior therapy for cutaneous lesions from Kaposi's sarcoma or lymphoproliferative disorders. Allowed: * Prior maintenance steroids and hormone/antihormone therapy.

Exclusion criteria

Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active infections other than medically stable HIV infection. * Active congestive heart failure, any persistent arrhythmia or transient serious arrhythmia (ventricular tachycardia, sinoatrial arrest, etc.), or progressive cardiomyopathy. * Unstable blood pressure. * Seizures or other CNS disorders. * Severe unstable diabetes mellitus. * Coagulopathies. * Thrombotic disease. * Any other medical conditions that would prevent completion of study or produce significant risk to patient. Concurrent Medication: Excluded: * Concomitant chemotherapy or immunotherapy. * Ongoing corticosteroid therapy (unless maintenance). Patients with the following prior conditions are excluded: * History of active cardiopulmonary or respiratory disease. * History of sun hypersensitivity and photosensitive dermatoses. * History of allergy or hypersensitivity to cosmetics, toiletries, or other dermatological products.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026